Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Wins One Loses Another With U.S. FDA Approval Of Edarbi, Japan Withdrawal Of Dasen

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceutical Co. is feeling the ups and downs of drug making having announced U.S. FDA approval of the angiotensin II receptor blocker Edarbi days after announcing the withdrawal of its long-time anti-inflammatory drug Dasen from the Japanese market

You may also be interested in...



Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success

Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success

Takeda Submits NDA For Azilsartan With U.S. FDA To Expand Reach In Hypertension Market

Osaka-based Takeda Pharmaceutical April 28 submitted a new drug application with U.S. FDA for its angiotensin receptor blocker azilsartan and hopes to bank on the global success of candesartan to further its franchise in the hypertension treatment market

Latest News
See All
UsernamePublicRestriction

Register

SC077425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel